Navigation Links
Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
Date:2/28/2008

Robert G. Johnson, Jr. Resigns as President and Chief Executive Officer

Development Portfolio Focused on Near-Term Commercial Opportunities

HAYWARD, Calif., Feb. 28 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) today announced that Robert G. Johnson, Jr., M.D., Ph.D., has resigned as President and Chief Executive Officer and a member of Kosan's Board of Directors. Helen S. Kim, who joined Kosan in January 2008 as Senior Vice President and Chief Business Officer, has been appointed President of Kosan.

"Under Robert's leadership, Kosan made the successful transition from a research-oriented organization to a product development-focused company, and he has made many significant contributions to Kosan over the last eight years," said Peter Davis, Ph.D., Chairman of Kosan's Board of Directors. "Robert assumed the chief executive officer role during a period of transition and executed his responsibilities skillfully and energetically. He helped Kosan to manage a period of significant change to emerge as a better-positioned company and to recruit the senior management team that will help lead the company into its next phase. His commitment to Kosan has been intense, and his positive influence has been felt throughout the company. We express our sincerest thanks to Robert and wish him well in his new pursuits." Dr. Davis also noted: "Our new President, Helen Kim, has broad experience in product development and commercialization, as well as business and corporate development. These talents plus her demonstrated leadership will strengthen Kosan's ability to advance key product candidates toward the market."

Kosan also announced that the company has reprioritized its development portfolio. The compa
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
2. Kosan Announces February 28, 2008 Conference Call and Webcast
3. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
4. Kosan Announces Third Quarter 2007 Financial Results
5. Kosan to Reacquire Epothilone Program From Roche
6. Kosan Biosciences to Host Research & Development Day on October 31, 2007
7. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
8. Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference
9. Kosan Biosciences to Present at the Bear Stearns 20th Annual Healthcare Conference
10. Wyeth Announces Executive Change in Finance Organization
11. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...AN FRANCISCO, Dec. 1 Med...I) announced today that in tests involving its pro...to break "6 log" decontamination barriers, this ti... Claustridium difficile and Bacillis subtilis. The... extremely potent sporicidal technology. "The impl...
(Date:12/1/2009)... DNA Genotek, a leading provider of pro...unced that Tepnel Pharmaceutical Services will off... of its nucleic acid extraction and genotyping ser...) December 1, 2009 -- DNA Genotek , a leading pro..., today announced that Tepnel Pharmaceutical Serv...
(Date:12/1/2009)... iCardiac now provides services to thre.... , Rochester, NY (PRWEB)...a global leader in advanced cardiac core lab servi...ve pharmaceutical company has selected iCardiac as...rdiac will provide Highly Automated QT(sm) and Dyn...
(Date:11/30/2009)...OLUMBUS, Ohio, Nov. 30 The Ohio Ca...f the nation,s first minority business early-stage...and December 3, is called "Transforming the Landsc...rly-Stage Capital Summit." It will feature several...usiness leaders and local minority entrepreneurs. ...
Breaking Biology Technology:Medizone International Takes Aim at the Bioterrorism Countermeasures Arena 2Tepnel Pharmaceutical Services to Offer DNA Genotek's Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 2Tepnel Pharmaceutical Services to Offer DNA Genotek's Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 3Another Top Five Pharmaceutical Company Selects iCardiac as Preferred Provider of ECG Core Lab Services 2Ohio Capital Fund Announces Sponsorship of Minority Business Conference 2
... , Introduction , CypHer5 TM is a...-fluorescent at pH 7.4 and maximally fluorescent a...oring internalization of cell surface receptors vi...on (1, 2). , <P ,>In the assay, the re...nizing the tag is then labelled with CypHer5. Alte...
... , Key words: adenoviral vector &#...ll Analyzer ● gene delivery, , ...mary cells can greatly aid secondary screening as ...lopment presents several challenges. Establishing ...erest at detectable levels takes time. In addition...
... , Key words: Melanocortin • ...A Imaging Beads, , Pro-melanocorti... are processed into three major peptide hormone fr...te stimulating hormones, and β-endorphin. The... to activate the MC 5 (melanocortin subtype 5) re...
Other Biology Technology:The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR 2The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR 3The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR 4The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR 5The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR 6Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 2Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 3Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 4Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 5Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 6Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 7Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 8The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 2The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 3The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 4The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 5
(Date:12/1/2009)...ks by sharks can be solved with a new technique th...y put on their victims, according to a University ...ethod analogous to analyzing human fingerprints, s...mparing shark bites to the jaws and teeth of the p...f the International Shark Attack File, which is ho...
(Date:12/1/2009)...y-led international research team has developed an...neration of solar cells. , Scientists at Monash ...the universities of Wollongong and Ulm in Germany,...ith a three-fold increase in energy conversion eff...ye-sensitised solar cells. , Lead researcher Dr...
(Date:12/1/2009)...ble mystery, and it is a question which has contin...wering plants evolve and how did they come to domi...y Letters reveals the evolutionary trigger which ...etitive advantage over rival species, leading to t... by Dr Tim Brodribb and Dr Taylor Field of the Un...
Breaking Biology News(10 mins):New forensic technique gives clues about sharks from bite damage 2New forensic technique gives clues about sharks from bite damage 3Innovation puts next-generation solar cells on the horizon 2How did flowering plants evolve to dominate Earth? 2China Pharma Holdings Inc to Present at Brean Murray China Growth Conference 14881 1China Pharma Holdings Inc to Present at Brean Murray China Growth Conference 14881 2Oncolytics Biotech 28R 29 Inc Announces Unit Offering 14879 1Oncolytics Biotech 28R 29 Inc Announces Unit Offering 14879 2Oncolytics Biotech 28R 29 Inc Announces Unit Offering 14879 3Oncolytics Biotech 28R 29 Inc Announces Unit Offering 14879 4Quest Diagnostics Announces Pricing of Tender Offer for Any and All of Certain of its Outstanding Notes 6360 1Quest Diagnostics Announces Pricing of Tender Offer for Any and All of Certain of its Outstanding Notes 6360 2Quest Diagnostics Announces Pricing of Tender Offer for Any and All of Certain of its Outstanding Notes 6360 3Quest Diagnostics Announces Pricing of Tender Offer for Any and All of Certain of its Outstanding Notes 6360 4
...rst, scientists from Weill Cornell Medical College...ibed the specifics of how brain cells process anti...novel findings could prove useful in the developme...t of psychiatric diseases, most notably in the are...atured as the cover story in a recent issue of Mo...
...versity has received a three-year, $1.6 million gr...ductive science research focused on understanding ...unding fertilization and early embryonic developme...ilization and create a new cell called the zygote....ely forming a new individual. How do the egg and s...
...s, Inc., a fully,integrated critical care biothera...d and Drug Administration (FDA) has granted orphan...use in the reduction of the incidence and,severity...going solid organ,transplantation., Ralf Rosskamp...evelopment for Ikaria, commented, "The designation...
Other Biology News:N.Y. research team discovers how antidepressants and cocaine interact with brain cell targets 2N.Y. research team discovers how antidepressants and cocaine interact with brain cell targets 3W.M. Keck Foundation grant funds reproductive science research 2W.M. Keck Foundation grant funds reproductive science research 3Ikaria(R) Receives FDA Orphan Drug Designation for Inhaled Carbon Monoxide for Delayed Graft Function in Solid Organ Transplants 2
Giemsa stain from Sigma-Aldrich
Giemsa stain from Sigma-Aldrich
...om EVO384R are fast multi-channel pipetting platfo...e different sizes, with a multi-channel head and a... time saving, with true parallel processing of sam...he Freedom EVOware program. Each of these roboti...
SigmaScreen APS Coated Slides for Microarrays from Sigma-Aldrich
Biology Products: